Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis

Arthritis and Rheumatism

Volumn 63, Issue 6, 2011, Pages 1748-1757

  Terrier, Benjamin ^a   Semoun, Oren ^b   Saadoun, David ^a   Sène, Damien ^a   Resche Rigon, Matthieu ^b   Cacoub, Patrice ^a,c  

^a CNRS   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE SEVERITY; FEMALE; FIVE FACTORS SCORE; FOLLOW UP; HEART DISEASE; HEPATITIS C; HUMAN; KIDNEY DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; SYSTEMIC VASCULITIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; SYSTEMIC VASCULITIS; TREATMENT OUTCOME;

EID: 79958064689     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30319     Document Type: Article

References (33)

1. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69: 287-308. (Pubitemid 10036826)
2. Cacoub P, Costedoat-Chalumeau N, Lidove O, Alric L,. Cryoglobulinemia vasculitis. Curr Opin Rheumatol 2002; 14: 29-35. (Pubitemid 34059886)
3. Sansonno D, Dammacco F,. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005; 5: 227-36. (Pubitemid 40410068)
4. Mazzaro C, Franzin F, Tulissi P, Pussini E, Crovatto M, Carniello GS, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to α-interferon therapy. Cancer 1996; 77: 2604-13. (Pubitemid 126497594)
5. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991; 34: 1606-10.
6. Agnello V, Chung RT, Kaplan LM,. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-5.
7. Cacoub P, Fabiani FL, Musset L, Perrin M, Frangeul L, Leger JM, et al. Mixed cryoglobulinemia and hepatitis C virus. Am J Med 1994; 96: 124-32. (Pubitemid 24070530)
8. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al, for the MULTIVIRC Group. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999; 42: 2204-12. (Pubitemid 30263607)
9. Vassilopoulos D, Calabrese LH,. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies [review]. Arthritis Rheum 2002; 46: 585-97. (Pubitemid 34214240)
10. Terrier B, Sene D, Dechartres A, Saadoun D, Ortonne N, Rouvier P, et al. Systemic vasculitis in patients with hepatitis C virus infection with and without detectable mixed cryoglobulinemia. J Rheumatol 2011; 38: 104-10.
11. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355-74. (Pubitemid 38887136)
12. Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-23.
13. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N,. Cryoglobulinemia: a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40: 837-56.
14. Della Rossa A, Tavoni A, D'Ascanio A, Catarsi E, Marchi F, Bencivelli W, et al. Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus. Scand J Rheumatol 2010; 39: 167-70.
15. Ramos-Casals M, Robles A, Brito-Zeron P, Nardi N, Nicolas JM, Forns X, et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006; 36: 189-96. (Pubitemid 44773710)
16. Landau DA, Scerra S, Sene D, Resche-Rigon M, Saadoun D, Cacoub P,. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. J Rheumatol 2010; 37: 615-21.
17. Jennette JC, Falk RJ,. Small-vessel vasculitis. N Engl J Med 1997; 337: 1512-23. (Pubitemid 27495778)
18. Lightfoot RW Jr, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33: 1088-93. (Pubitemid 20273292)
19. Saadoun D, Terrier B, Semoun O, Sene D, Maisonobe T, Musset L, et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken) 2011; 63: 427-35.
20. Musset L, Diemert MC, Taibi F, Thi Huong Du L, Cacoub P, Leger JM, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992; 38: 798-802.
21. Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, et al. Interferon-α and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002; 46: 3317-26. (Pubitemid 35453543)
22. The French Metavir Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
23. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T,. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75. (Pubitemid 32322537)
24. Jaffe ES,. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009: 523-31.
25. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 17-28. (Pubitemid 26041085)
26. Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al, for the French Vasculitis Study Group. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group database. Arthritis Rheum 2010; 62: 616-26.
27. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-96. (Pubitemid 44470696)
28. Kristiansen MG, Lochen ML, Gutteberg TJ, Mortensen L, Eriksen BO, Florholmen J,. Total and cause-specific mortality rates in a prospective study of community-acquired hepatitis C virus infection in northern Norway. J Viral Hepat 2011; 18: 237-44.
29. Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN,. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 2002; 36: 978-85.
30. Saadoun D, Asselah T, Resche-Rigon M, Charlotte F, Bedossa P, Valla D, et al. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology 2006; 43: 1337-45. (Pubitemid 43980113)
31. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al, and the French Vaculitis Study Group. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-75. (Pubitemid 32234626)
32. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P,. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006; 54: 3696-706. (Pubitemid 44737183)
33. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ,. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007; 297: 278-85. (Pubitemid 46143305)